|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Neuro-Oncology |
Department of Neuro-Oncology, Dr. Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands (M.v.d.B.); Hôpital de la Timone, Service de Neurochirurgie, Boulevard Jean Moulin, 13385 Marseille, France (O.-L.C.); Department of Clinical Neurosciences, University of Calgary and Foothills Medical Centre, 1403 29th Street N.W., Calgary, Alberta T2N 2T9, Canada (S.G.C.)
1 Address correspondence and reprint requests to Martin van den Bent, Department of Neuro-Oncology, Dr. Daniel den Hoed Cancer Center, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands
Abstract
Although many patients with oligodendrogliomas (ODs) and oligoastrocytomas (OAs) benefit from a combination of surgery and adjuvant radiotherapy, most patients eventually experience recurrence of their disease. Recent evidence has shown that ODs are more chemosensitive than other gliomas, including astrocytomas or glioblastoma multiforme. These initial findings have prompted further study of chemotherapy in treating ODs and mixed OAs. Advances in molecular genetic analysis have led to improvements in predicting response to chemotherapy and prognosis for ODs, OAs, and astrocytomas. Pure ODs are more chemosensitive than mixed ODs. This difference is related to different proportions of 1p/19q loss of heterozygosity in these neoplasms. Therefore, genetic analysis is likely to be key in determining appropriate treatment. The most common first-line chemotherapy for patients with OD is a procarbazine, lomustine, and vincristine (PCV) combination regimen. However, this regimen is associated with cumulative myelosuppression, nausea, vomiting, and weight loss. Therefore, other chemotherapy agents and regimens have been investigated. Perhaps the most promising is temozolomide, a novel alkylating agent that freely crosses the blood-brain barrier. Temozolomide is approved in the United States for the treatment of recurrent anaplastic astrocytomas and in Europe for any recurrent high-grade gliomas. Initial reports suggest that temozolomide is effective in treating ODs as first- and second-line chemotherapy. Unlike the PCV regimen, temozolomide is not associated with cumulative myelosuppression and is usually well tolerated. Further studies are needed to confirm the efficacy and safety profile of temozolomide and to determine the optimal dose and schedule for treating ODs.
References
Allam, A., Radwi, A., El Weshi, A., and Hassounah, M. (2000) Oligodendroglioma: An analysis of prognostic factors and treatment results. Am. J. Clin. Oncol. 23,170 -175.[CrossRef][ISI][Medline]
Allison, R.R., Schulsinger, A., Vongtama, V., Barry, T., and Shin, K.H. (1997) Radiation and chemotherapy improve outcome in oligodendroglioma. Int. J. Radiat. Oncol. Biol. Phys. 37,399 -403.[CrossRef][ISI][Medline]
Bauman, G.S., and Cairncross, J.G. (2001) Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligoastrocytomas. Semin. Radiat. Oncol. 11,170 -180.[CrossRef][ISI][Medline]
Bauman, G.S., Ino, Y., Ueki, K., Zlatescu, M.C., Fisher, B.J., Macdonald, D.R., Stitt, L., Louis, D.N., and Cairncross, J.G. (2000) Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int. J. Radiat. Oncol. Biol. Phys. 48,825 -830.[CrossRef][ISI][Medline]
Berger, M.S., Deliganis, A.V., Dobbins, J., and Keles, G.E. (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74,1784 -1791.[CrossRef][ISI][Medline]
Bigner, S.H., Matthews, M.R., Rasheed, B.K.A., Wiltshire, R.N.,
Friedman, H.S., Friedman, A.H., Stenzel, T.T., Dawes, D.M., McLendon, R.E.,
and Bigner, D.D. (1999) Molecular genetic aspects of
oligodendrogliomas including analysis by comparative genomic hybridization.
Am. J. Pathol. 155,375
-386.
Bower, M., Newlands, E.S., Bleehen, N.M., Brada, M., Begent, R.J., Calvert, H., Colquhoun, I., Lewis, P., and Brampton, M.H. (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. 40,484 -488.[CrossRef][ISI][Medline]
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.Y., Dirix,
L.Y., Macdonald, D., Heimans, J.J., Zonnenberg, B.A., Bravo-Marques, J.M.,
Henriksson, R., Stupp, R., Yue, N., Bruner, J., Dugan, M., Rao, S., and
Zaknoen, S. (2001) Multicenter phase II trial of temozolomide in
patients with glioblastoma multiforme at first relapse. Ann.
Oncol. 12,259
-266.
Brandes, A.A., Ermani, M., Basso, U., Amista, P., Berti, F.,
Scienza, R., Rotilio, A., Pinna, G., Gardiman, M., and Monfardini, S.
(2001) Temozolomide as a second-line systemic regimen in
recurrent high-grade glioma: A phase II study. Ann.
Oncol. 12,255
-257.
Bullard, D.E., Rawlings, C.E., 3rd, Phillips, B., Cox, E.B., Schold, S.C., Jr., Burger, P., and Halperin, E.C. (1987) Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 60,2179 -2188.[CrossRef][ISI][Medline]
Burger, P.C., Vogel, F.S., Green, S.B., and Strike, T.A. (1985) Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56,1106 -1111.[CrossRef][ISI][Medline]
Burger, P.C., Rawlings, C.E., Cox, E.B., McLendon, R.E., Schold, S.C., Jr., and Bullard, D.E. (1987) Clinicopathologic correlations in the oligodendroglioma. Cancer 59,1345 -1352.[CrossRef][ISI][Medline]
Cairncross, J.G., and Macdonald, D.R. (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23,360 -364.[CrossRef][ISI][Medline]
Cairncross, J.G., and Macdonald, D.R. (1991) Chemotherapy for oligodendroglioma. Progress report. Arch. Neurol. 48,225 -227.[ISI][Medline]
Cairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T.,
Buckner, J., Fulton, D., Dropcho, E., Stewart, D., and Schold, C., Jr.
(1994) Chemotherapy for anaplastic oligodendroglioma. National
Cancer Institute of Canada Clinical Trials Group. J. Clin.
Oncol. 12,2013
-2021.
Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K.,
Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R.,
Ino, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic
predictors of chemotherapeutic response and survival in patients with
anaplastic oligodendrogliomas. J. Natl. Cancer Inst.
90,1473
-1479.
CBTRUS (Central Brain Tumor Registry of the United States).Year 2001 Annual Statistics Report: Brain Tumors in the US 1992–1997 . Available at http://www.cbtrus.org/2001/2001stats_report.htm
Celli, P., Nofrone, I., Palma, L., Cantore, G., and Fortuna, A. (1994) Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35, 1018-1034; discussion 1034-1035.[ISI][Medline]
Chamberlain, M.C. (2001) A phase1 -2 trial of CPT-11 (Camptosar) in the treatment of recurrent intracranial oligodendrogliomas [oligos]. Neurooncol. 3, 356. (Abstract)[Abstract]
Chamberlain, M.C., and Kormanik, P.A. (1997) Salvage
chemotherapy with paclitaxel for recurrent oligodendrogliomas J.
Clin. Oncol. 15,3427
-3432.
Chinot, O.L., Barrie, M., Dufour, H., Romain, S., Ouafik, L., Figarella, D., Martin, P., and Grisoli, F. (2001a) Resistance of anaplastic oligodendroglioma (AO) to procarbazine-CCNU-vincristine (PCV) is correlate to a glioblastoma phenotype. Proc. Am. Soc. Clin. Oncol. 20,2060 . (Abstract)
Chinot, O.L., Honore, S., Dufour, H., Barrie, M.,
Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.M., and Grisoli,
F. (2001b) Safety and efficacy of temozolomide in patients with
recurrent anaplastic oligodendrogliomas after standard radiotherapy and
chemotherapy. J. Clin. Oncol.
19,2449
-2455.
Coons, S.W., Johnson, P.C., Scheithauer, B.W., Yates, A.J., and Pearl, D.K. (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79,1381 -1393.[CrossRef][ISI][Medline]
Costanza, A., Borgognone, M., Nobile, M., Rudà, R., Mutani, R., and Soffietti, R. (2001) Temozolomide in recurrent oligodendroglial tumors: A phase II study. Neuro-oncol. 3 (Suppl. 1), 66. (Abstract)
Daumas-Duport, C., Varlet, P., Tucker, M.L., Beuvon, F., Cervera, P., and Chodkiewicz, J.P. (1997a) Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases. J. Neurooncol. 34, 37-59.[CrossRef][Medline]
Daumas-Duport, C., Tucker, M.L., Kolles, H., Cervera, P., Beuvon, F., Varlet, P., Udo, N., Koziak, M., and Chodkiewicz, J.P. (1997b) Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J. Neurooncol. 34, 61-78.[CrossRef][Medline]
Dehghani, F., Schachenmayr, W., Laun, A., and Korf, H.W. (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases. Acta Neuropathol. (Berl.) 95,493 -504.[CrossRef][Medline]
Donahue, B., Scott, C.B., Nelson, J.S., Rotman, M., Murray, K.J., Nelson, D.F., Banker, F.L., Earle, J.D., Fischbach, J.A., Asbell, S.O., Gaspar, L.E., Markoe, A.M., and Curran, W. (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of Radiation Therapy Oncology Group 83–02. Int. J. Radiat. Oncol. Biol. Phys. 38,911 -914.[CrossRef][ISI][Medline]
Friedman, H.S., McLendon, R.E., Kerby, T., Dugan, M., Bigner, S.H.,
Henry, A.J., Ashley, D.M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F.,
Seman, A.J., Cokgor, I., Rich, J., Stewart, E., Colvin, O.M., Provenzale,
J.M., Bigner, D.D., Haglund, M.M., Friedman, A.H., and Modrich, P.L.
(1998) DNA mismatch repair and O6-alkylguanine-DNA
alkyltransferase analysis and response to Temodal in newly diagnosed malignant
glioma. J. Clin. Oncol.
16,3851
-3857.
Gannett, D.E., Wisbeck, W.M., Silbergeld, D.L., and Berger, M.S. (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int. J. Radiat. Oncol. Biol. Phys. 30,567 -573.[ISI][Medline]
Giannini, C., Scheithauer, B.W., Weaver, A.L., Burger, P.C., Kros, J.M., Mork, S., Graeber, M.B., Bauserman, S., Buckner, J.C., Burton, J., Riepe, R., Tazelaar, H.D., Nascimento, A.G., Crotty, T., Keeney, G.L., Pernicone, P., and Altermatt, H. (2001) Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading. J. Neuropathol. Exp. Neurol. 60,248 -262.[ISI][Medline]
Greenlee, R.T., Hill-Harmon, M.B., Murray, T., and Thun, M.
(2001) Cancer statistics, 2001 [erratum in CA Cancer J.
Clin. 51, 144] CA Cancer J. Clin.
51, 15-36.
Hoang-Xuan, K., He, J., Huguet, S., Mokhtari, K., Marie, Y., Kujas,
M., Leuraud, P., Capelle, L., Delattre, J.Y., Poirier, J., Broet, P., and
Sanson, M. (2001) Molecular heterogeneity of oligodendrogliomas
suggests alternative pathways in tumor progression.
Neurology 57,1278
-1281.
Ino, Y., Betensky, R.A., Zlatescu, M.C., Sasaki, H., Macdonald,
D.R., Stemmer-Rachamimov, A.O., Ramsay, D.A., Cairncross, J.G., and Louis,
D.N. (2001) Molecular subtypes of anaplastic oligodendroglioma:
Implications for patient management at diagnosis. Clin. Cancer
Res. 7,839
-845.
Jeuken, J.W., Sprenger, S.H., Wesseling, P., Macville, M.V., von Deimling, A., Teepen, H.L., van Overbeeke, J.J., and Boerman, R.H. (1999) Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J. Neuropathol. Exp. Neurol. 58,606 -612.[ISI][Medline]
Jeuken, J.W., Nelen, M.R., Vermeer, H., van Staveren, W.C., Kremer, H., van Overbeeke, J.J., and Boerman, R.H. (2000) PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors. PTEN is only occasionally mutated in one of the two genetic subtypes. Cancer Genet. Cytogenet. 119, 42-47.[CrossRef][ISI][Medline]
Kleihues, P., Burger, P.C., and Scheithauer, B.W. (1993) The new WHO classification of brain tumours. Brain Pathol. 3,255 -268.[ISI][Medline]
Kraus, J.A., Koopmann, J., Kaskel, P., Maintz, D., Brandner, S., Schramm, J., Louis, D.N., Wiestler, O.D., and von Deimling, A. (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol. 54,91 -95.[ISI][Medline]
Kros, J.M., Pieterman, H., van Eden, C.G., and Avezaat, C.J. (1994) Oligodendroglioma: The Rotterdam-Dijkzigt experience. Neurosurgery 34,959 -966; discussion 966.[ISI][Medline]
Krouwer, H.G., van Duinen, S.G., Kamphorst, W., van der Valk, P., and Algra, A. (1997) Oligoastrocytomas: A clinicopathological study of 52 cases. J. Neurooncol. 33,223 -238.[CrossRef][Medline]
Kyritsis, A.P., Yung, W.K., Bruner, J., Gleason, M.J., and Levin, V.A. (1993) The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32, 365-370; discussion 371.[ISI][Medline]
Leighton, C., Fisher, B., Bauman, G., Depiero, S., Stitt, L.,
MacDonald, D., and Cairncross, G. (1997) Supratentorial low-grade
glioma in adults: An analysis of prognostic factors and timing of radiation.
J. Clin. Oncol. 15,1294
-1301.
Louis, D.N., and Cavenee, W.K. (2001) Neoplasms of the central nervous system. In: DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.), Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, pp.2091 -2100.
Lu, Q.R., Park, J.K., Noll, E., Chan, J.A., Alberta, J., Yuk, D.,
Alzamora, M.G., Louis, D.N., Stiles, C.D., Rowitch, D.H., and Black, P.M.
(2001) Oligodendrocyte lineage genes (OLIG) as molecular markers
for human glial brain tumors. Proc. Natl. Acad. Sci.
U.S.A. 98,10851
-10856.
Macdonald, D.R. (1994) Low-grade gliomas, mixed gliomas, and oligodendrogliomas. Semin. Oncol. 21,236 -248.[ISI][Medline]
Maintz, D., Fiedler, K., Koopmann, J., Rollbrocker, B., Nechev, S., Lenartz, D., Stangl, A.P., Louis, D.N., Schramm, J., Wiestler, O.D., and von Deimling, A. (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 56,1098 -1104.[ISI][Medline]
Marie, Y., Sanson, M., Mokhtari, K., Leuraud, P., Kujas, M., Delattre, J.Y., Poirier, J., Zalc, B., and Hoang-Xuan, K. (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358,298 -300.[CrossRef][ISI][Medline]
Marzolini, C., Decosterd, L.A., Shen, F., Gander, M., Leyvraz, S., Bauer, J., Buclin, T., Biollaz, J., and Lejeune, F. (1998) Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration [erratum in Cancer Chemother. Pharmacol. 43, 439–440, 1999]. Cancer Chemother. Pharmacol. 42,433 -440.[CrossRef][ISI][Medline]
Mason, W.P., Krol, G.S., and DeAngelis, L.M. (1996)
Low-grade oligodendroglioma responds to chemotherapy.
Neurology 46,203
-207.
Mork, S.J., Lindegaard, K.F., Halvorsen, T.B., Lehmann, E.H., Solgaard, T., Hatlevoll, R., Harvei, S., and Ganz, J. (1985) Oligodendroglioma: Incidence and biological behavior in a defined population. J. Neurosurg. 63,881 -889.[ISI][Medline]
Newlands, E.S., O'Reilly, S.M., Glaser, M.G., Bower, M., Evans, H., Brock, C., Brampton, M.H., Colquhoun, I., Lewis, P., Rice-Edwards, J.M., Illingworth, R.D., and Richards, P.G. (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer 32A,2236 -2241.
Nijjar, T.S., Simpson, W.J., Gadalla, T., and McCartney, M. (1993) Oligodendroglioma. The Princess Margaret Hospital experience (1958–1984). Cancer 71,4002 -4006.[CrossRef][ISI][Medline]
Nobile, M., Costanza, A., Rudà, R., Mutani, R., and Soffietti, R. (2001) Salvage chemotherapy with carboplatin for recurrent oligodendroglial tumors. Neuro-oncol. 3, 362. (Abstract)
Olson, J.D., Riedel, E., and DeAngelis, L.M. (2000)
Long-term outcome of low-grade oligodendroglioma and mixed glioma.
Neurology 54,1442
-1448.
O'Reilly, S.M., Newlands, E.S., Glaser, M.G., Brampton, M., Rice-Edwards, J.M., Illingworth, R.D., Richards, P.G., Kennard, C., Colquhoun, I.R., Lewis, P., and Stevens, M.F.G. (1993) Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours [erratum in Eur. J. Cancer 29A:1500, 1993]. Eur. J. Cancer. 29A,940 -942.
Paleologos, N.A., Vick, N.A., and Kachoris, J.P. (1994) Chemotherapy for low-grade oligodendrogliomas? Ann. Neurol. 36,294 -295. (Abstract)
Paleologos, N.A., Macdonald, D.R., Vick, N.A., and Cairncross, J.G.
(1999) Neoadjuvant procarbazine, CCNU, and vincristine for
anaplastic and aggressive oligodendroglioma. Neurology
53,1141
-1143.
Peterson, K., Paleologos, N., Forsyth, P., Macdonald, D.R., and Cairncross, J.G. (1996) Salvage chemotherapy for oligodendroglioma. J. Neurosurg. 85,597 -601.[ISI][Medline]
Reedy, D.P., Bay, J.W., and Hahn, J.F. (1983) Role of radiation therapy in the treatment of cerebral oligodendroglioma: An analysis of 57 cases and a literature review. Neurosurgery 13,499 -503.[ISI][Medline]
Reifenberger, G., Kros, J.M., Burger, P., Louis, D.N., Collins, V.P. (2000) Oligodendroglioma. In: Kleihues, P., Cavanee, W.K. (Eds.), World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC Press, pp. 55-70.
Reifenberger, J., Reifenberger, G., Liu, L., James, C.D., Wechsler, W., and Collins, V.P. (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 145,1175 -1190.[Abstract]
Ries, L.A.G., Eisner, M.P., Kosary, C.L., Hankey, B.F., Miller, B.A., Clegg, L., and Edwards, B.K. (Eds.). (2001) SEER Cancer Statistics Review, 1973–1998, Bethesda, Maryland: National Cancer Institute. Available at http://seer.cancer.gov/csr/1973_1998
Sasaki, H., Zlatescu, M.C., Betensky, R.A., Ino, Y., Cairncross,
J.G., and Louis, D.N. (2001) PTEN is a target of chromosome 10q
loss in anaplastic oligodendrogliomas and PTEN alterations are associated with
poor prognosis. Am. J. Pathol.
159,359
-367.
Sasaki, H., Zlatescu, M.C., Betensky, R.A., Johnk, L.B., Cutone, A.N., Cairncross, J.G., and Louis, D.N. (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma." J. Neuropathol. Exp. Neurol. 61,58 -63.[ISI][Medline]
Schiffer, D., Dutto, A., Cavalla, P., Bosone, I., Chio, A., Villani, R., and Bellotti, C. (1997) Prognostic factors in oligodendroglioma. Can. J. Neurol. Sci. 24,313 -319.[ISI][Medline]
Shaw, E.G., Scheithauer, B.W., O'Fallon, J.R., Tazelaar, H.D., and Davis, D.H. (1992) Oligodendrogliomas: The Mayo Clinic experience. J. Neurosurg. 76,428 -434.[ISI][Medline]
Shaw, E.G., Scheithauer, B.W., O'Fallon, J.R., and Davis, D.H. (1994) Mixed oligoastrocytomas: A survival and prognostic factor analysis. Neurosurgery 34, 577-582; discussion 582.[ISI][Medline]
Shaw, E.G., Scheithauer, B.W., and O'Fallon, J.R. (1997) Supratentorial gliomas: A comparative study by grade and histologic type. J. Neurooncol. 31,273 -278.[CrossRef][Medline]
Shoshan, Y., Nishiyama, A., Chang, A., Mork, S., Barnett, G.H.,
Cowell, J.K., Trapp, B.D., and Staugaitis, S.M. (1999) Expression
of oligodendrocyte progenitor cell antigens by gliomas: Implications for the
histogenesis of brain tumors. Proc. Natl. Acad. Sci.
U.S.A. 96,10361
-10366.
Smith, J.S., Alderete, B., Minn, Y., Borell, T.J., Perry, A., Mohapatra, G., Hosek, S.M., Kimmel, D., O'Fallon, J., Yates, A., Feuerstein, B.G., Burger, P.C., Scheithauer, B.W., and Jenkins, R.B. (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18,4144 -4152.[CrossRef][ISI][Medline]
Smith, J.S., Perry, A., Borell, T.J., Lee, H.K., O'Fallon, J.,
Hosek, S.M., Kimmel, D., Yates, A., Burger, P.C., Scheithauer, B.W., and
Jenkins, R.B. (2000) Alterations of chromosome arms 1p and 19q as
predictors of survival in oligodendrogliomas, astrocytomas, and mixed
oligoastrocytomas. J. Clin. Oncol.
18,636
-645.
Soffietti, R., Rudà, R., Bradac, G.B., and Schiffer, D. (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43,1066 -1073.[CrossRef][ISI][Medline]
Soffietti, R., Rudà, R., Borgognone, M., and Schiffer, D. (1999) Chemotherapy with PCV for low grade nonenhancing oligodendrogliomas and oligoastrocytomas. Neurology 52 (Suppl. 2),A423 -A424. (Abstract)
Stevens, M.F., Hickman, J.A., Langdon, S.P., Chubb, D., Vickers,
L., Stone, R., Baig, G., Goddard, C., Gibson, N.W., and Slack, J.A.
(1987) Antitumor activity and pharmacokinetics in mice of
8–carbamoyl-3–methyl-imidazo[5,1–d]-1,2,3,5–tetrazin-4(3H)-one
(CCRG 81045; M & B 39831), a novel drug with potential as an alternative
to dacarbazine. Cancer Res.
47,5846
-5852.
Streffer, J., Schabet, M., Bamberg, M., Grote, E.H., Meyermann, R., Voigt, K., Dichgans, J., and Weller, M. (2000) A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J. Neurol. 247,297 -302.[CrossRef][ISI][Medline]
Stupp, R., Ostermann, S., Leyvraz, S., Csajka, C., Buclin, T., and Decosterd, L.A. (2001) Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc. Am. Soc. Clin. Oncol. 20,59 (Abstract)
Surma-aho, O., Niemela, M., Vilkki, J., Kouri, M., Brander, A.,
Salonen, O., Paetau, A., Kallio, M., Pyykkonen, J., and Jaaskelainen, J.
(2001) Adverse long-term effects of brain radiotherapy in adult
low-grade glioma patients. Neurology
56,1285
-1290.
Taphoorn, M.J., Schiphorst, A.K., Snoek, F.J., Lindeboom, J., Wolbers, J.G., Karim, A.B., Huijgens, P.C., and Heimans, J.J. (1994) Cognitive functions and quality of life in patients with low-grade gliomas: The impact of radiotherapy. Ann. Neurol. 36,48 -54.[CrossRef][ISI][Medline]
van den Bent, M.J. (2000) Chemotherapy of oligodendroglial tumours: Current developments. Forum (Genova) 10,108 -118.
van den Bent, M.J., Kros, J.M., Heimans, J.J., Pronk, L.C., van
Groeningen, C.J., Krouwer, H.G.J., Taphoorn, M.J.B., Zonnenberg, B.A.,
Tijssen, C.C., Twijnstra, A., Punt, C.J.A., and Boogerd, W.
(1998) Response rate and prognostic factors of recurrent
oligodendroglioma treated with procarbazine, CCNU, and vincristine
chemotherapy. Dutch Neuro-oncology Group. Neurology
51,1140
-1145.
van den Bent, M.J., Keime-Guibert, F., Brandes, A.A., Taphoorn,
M.J.B., Kros, J.M., Eskens, F.A.L.M., and Carpentier, A.F. (2001)
Temozolomide chemotherapy in recurrent oligodendroglioma.
Neurology 57,340
-342.
van den Bent, M.J., van der Rijt, C.D.D., Enting, R.H., van de Heuvel, I., Sillevis Smitt, P.A.E., ter Steegh, E., Dijke, I.E., Looijenga, L., and Kros, J.M. (2002a) PCV chemotherapy in newly diagnosed and recurrent low grade oligodendroglial tumors. Neuro-oncol. 4,378 . (Abstract)
van den Bent, M.J., Taphoorn, M.J.B., Brandes, A.A., Menten, J., Stupp, R., Frenay, M., van der Rijt, C.C.D., Kros, J.M., Allgeier, A., and Gorlia, T. (2002b) EORTC brain tumor group study 26971: First line chemotherapy with temozolomide in recurrent oligodendroglial tumors; a phase II study. Proc. Am. Soc. Clin. Oncol. 21, 72. (Abstract)
van den Bent, M.J., Chinot, O., Boogerd, W., Bravo-Marques, J., Taphoorn, M.J., Kros, J., van de Rijt, C., de Beule, N., and Baron, B. (2003a) EORTC Brain Tumor Study 26972: Second line chemotherapy with Temozolomide in recurrent oligodendroglioma after PCV-chemotherapy: A phase II study. Ann. Oncol. 2003 (in press).
van den Bent, M.J., Looijenga, L.H.J., Langenberg, K., Dinjens, W.N., Graveland, W.J., Uytdewilligen, L., Sillevis Smitt, P.A.E., Jenkins, R.B., and Kros, J.M. (2003b) Chromosomal anomalies in oligodendroglial tumors are correlated to clinical features. Cancer (in press).
Walker, M.D., Alexander, E., Jr., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., Norrell, H.A., Owens, G., Ransohoff, J., Wilson, C.B., Gehan, E.A., and Strike, T.A. (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49,333 -343.[ISI][Medline]
Walker, M.D., Green, S.B., Byar, D.P., Alexander, E., Jr., Batzdorf, U., Brooks, W.H., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., Owens, G., Ransohoff, J., 2d, Robertson, J.T., Shapiro, W.R., Smith, K.R., Jr., Wilson, C.B., and Strike, T.A. (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303,1323 -1329.[Abstract]
Wallner, K.E., Gonzales, M., and Sheline, G.E. (1988) Treatment of oligodendrogliomas with or without postoperative irradiation. J. Neurosurg. 68,684 -688.[ISI][Medline]
Watanabe, T., Nakamura, M., Kros, J.M., Burkhard, C., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2002) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol. (Berl.) 103,267 -275.[CrossRef][Medline]
Winger, M.J., Macdonald, D.R., and Cairncross, J.G. (1989) Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J. Neurosurg. 71,487 -493.[ISI][Medline]
Yung, W.K.A., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada,
M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M.,
Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A.
(1999) Multicenter phase II trial of temozolomide in patients
with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse.
Temodal Brain Tumor Group [erratum in J. Clin. Oncol. 17,
3693, 1999]. J. Clin. Oncol.
17,2762
-2771.
Yung, W.K.A., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83,588 -593.[CrossRef][ISI][Medline]
Zlatescu, M.C., TehraniYazdi, A., Sasaki, H., Megyesi, J.F.,
Betensky, R.A., Louis, D.N., and Cairncross, J.G. (2001) Tumor
location and growth pattern correlate with genetic signature in
oligodendroglial neoplasms. Cancer Res.
61,6713
-6715.
This article has been cited by other articles:
|
|
 |
|
  M. J. van den Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. J.B. Taphoorn, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, et al. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial J. Clin. Oncol., June 20, 2006; 24(18): 2715 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Voloschin, D. N. Louis, G. R. Cosgrove, and T. T. Batchelor Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study Neuro-oncol, January 1, 2005; 7(1): 97 - 100. [Abstract] [PDF]
|
|
|
|
 |
|
 M. S. Bobola, M. J. Emond, A. Blank, E. H. Meade, D. D. Kolstoe, M. S. Berger, R. C. Rostomily, D. L. Silbergeld, A. M. Spence, and J. R. Silber Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy Clin. Cancer Res., December 1, 2004; 10(23): 7875 - 7883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lebrun, D. Fontaine, A. Ramaioli, F. Vandenbos, S. Chanalet, M. Lonjon, J. F. Michiels, V. Bourg, P. Paquis, M. Chatel, et al. Long-term outcome of oligodendrogliomas Neurology, May 25, 2004; 62(10): 1783 - 1787. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
